The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodiu...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3317955?pdf=render |
| _version_ | 1819024853066317824 |
|---|---|
| author | Tina S Skinner-Adams Alice S Butterworth Kimberly A Porter Ronald D'Amico Fred Sawe Doug Shaffer Abraham Siika Mina C Hosseinipour Elizabeth Stringer Judith S Currier Tsungai Chipato Robert Salata Shahin Lockman Joseph J Eron Steven R Meshnick James S McCarthy |
| author_facet | Tina S Skinner-Adams Alice S Butterworth Kimberly A Porter Ronald D'Amico Fred Sawe Doug Shaffer Abraham Siika Mina C Hosseinipour Elizabeth Stringer Judith S Currier Tsungai Chipato Robert Salata Shahin Lockman Joseph J Eron Steven R Meshnick James S McCarthy |
| author_sort | Tina S Skinner-Adams |
| collection | DOAJ |
| description | HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodium falciparum histidine-rich protein 2 antigen test, among 444 HIV-infected women initiating antiretroviral treatment (ART) in the OCTANE trial (A5208; ClinicalTrials.gov: NCT00089505). Participants were randomized to treatment with PI-containing vs. PI-sparing ART, and were followed prospectively for ≥48 weeks; 73% also received cotrimoxazole prophylaxis. PI-containing treatment was not associated with protection against malaria in this study population. |
| first_indexed | 2024-12-21T05:01:23Z |
| format | Article |
| id | doaj.art-e99ee49aba3447378d91bc184440e641 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T05:01:23Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e99ee49aba3447378d91bc184440e6412022-12-21T19:15:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0174e3439910.1371/journal.pone.0034399The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.Tina S Skinner-AdamsAlice S ButterworthKimberly A PorterRonald D'AmicoFred SaweDoug ShafferAbraham SiikaMina C HosseinipourElizabeth StringerJudith S CurrierTsungai ChipatoRobert SalataShahin LockmanJoseph J EronSteven R MeshnickJames S McCarthyHIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodium falciparum histidine-rich protein 2 antigen test, among 444 HIV-infected women initiating antiretroviral treatment (ART) in the OCTANE trial (A5208; ClinicalTrials.gov: NCT00089505). Participants were randomized to treatment with PI-containing vs. PI-sparing ART, and were followed prospectively for ≥48 weeks; 73% also received cotrimoxazole prophylaxis. PI-containing treatment was not associated with protection against malaria in this study population.http://europepmc.org/articles/PMC3317955?pdf=render |
| spellingShingle | Tina S Skinner-Adams Alice S Butterworth Kimberly A Porter Ronald D'Amico Fred Sawe Doug Shaffer Abraham Siika Mina C Hosseinipour Elizabeth Stringer Judith S Currier Tsungai Chipato Robert Salata Shahin Lockman Joseph J Eron Steven R Meshnick James S McCarthy The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. PLoS ONE |
| title | The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. |
| title_full | The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. |
| title_fullStr | The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. |
| title_full_unstemmed | The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. |
| title_short | The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. |
| title_sort | frequency of malaria is similar among women receiving either lopinavir ritonavir or nevirapine based antiretroviral treatment |
| url | http://europepmc.org/articles/PMC3317955?pdf=render |
| work_keys_str_mv | AT tinasskinneradams thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT alicesbutterworth thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT kimberlyaporter thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT ronalddamico thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT fredsawe thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT dougshaffer thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT abrahamsiika thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT minachosseinipour thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT elizabethstringer thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT judithscurrier thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT tsungaichipato thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT robertsalata thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT shahinlockman thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT josephjeron thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT stevenrmeshnick thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT jamessmccarthy thefrequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT tinasskinneradams frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT alicesbutterworth frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT kimberlyaporter frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT ronalddamico frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT fredsawe frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT dougshaffer frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT abrahamsiika frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT minachosseinipour frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT elizabethstringer frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT judithscurrier frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT tsungaichipato frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT robertsalata frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT shahinlockman frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT josephjeron frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT stevenrmeshnick frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment AT jamessmccarthy frequencyofmalariaissimilaramongwomenreceivingeitherlopinavirritonavirornevirapinebasedantiretroviraltreatment |